Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai Offers Indonesia 151 Million Tablets of Elephantiasis Drug for Free
October 6, 2015
- GSK to Seek COPD Indication for Relvar in January-March 2016
October 6, 2015
- Belsomra Most Heavily Pitched Drug in July: Anterio Ranking
October 5, 2015
- Japan OTC Drug Market Logs 1st Rise in 5 Years: Fuji Keizai
October 5, 2015
- Mitsubishi Tanabe Wins Rights to Regeneron’s NGF Antibody in Asia
October 5, 2015
- Otsuka Files Combination Glaucoma Eye Drops in Japan
October 2, 2015
- ASKA Takes Over 2 Anti-Thyroid Drugs from Chugai
October 2, 2015
- Active Promotion of HPV Vaccines Should Be Resumed: GSK
October 1, 2015
- Mitsubishi Tanabe Raises Full-Year Earnings Projection
October 1, 2015
- Nichi-Iko Files Remicade Biosimilar in Japan
October 1, 2015
- Sato, POLA to Jointly Market Clenafin Competitor Drug
October 1, 2015
- Eisai Ups April-Sept. Profit Forecasts on Lower Sales
October 1, 2015
- Asahi Kasei Pharma Seek Japan Approval of Once-Yearly Osteoporosis Drug
October 1, 2015
- Astellas Licenses Analgesic Ion Channel Blocker from US Chromocell
October 1, 2015
- Fujifilm to Establish Cellular Dynamics Japan for iPS Biz
September 30, 2015
- CMIC Holdings CEO to Double as OrphanPacific Chairman
September 30, 2015
- Halaven Now under FDA’s Priority Review for Soft Tissue Sarcoma: Eisai
September 30, 2015
- Janssen Seeks Pediatric Use for Ultiva in Japan
September 30, 2015
- Amgen Astellas Building Sales Force before PCSK9 Approval
September 29, 2015
- GSK to Compensate for Add’l Patient Burdens Tied to Hep B Drug Shortage
September 29, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…